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Capsule summary: 
e-MDSCs, defined as Linneg (CD3/CD14/CD15/CD19/CD56) HLA-DRneg CD33pos, have a 
phenotype that overlaps with basophils. For a proper quantification of e-MDSCs by flow 
cytometry, the gating strategy should specifically exclude basophils.  
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To the Editor: 
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells 
characterized by their immune suppressive functions.1 Circulating MDSCs are increased in 
inflammatory diseases, sepsis,2 and numerous cancers, including lymphoid malignancies3 and 
solid tumors. Their number increases with disease severity and predicts response to treatment 
and overall survival in various cancers.3,4 In septic patients, polymorphonuclear (PMN)-
MDSCs are specifically associated with the occurrence of nosocomial infections.2 
Consequently, these cells are becoming important biomarkers in several clinical situations 
and need as such to be accurately quantified. However, despite efforts in recent years to unify 
the nomenclature of MDSCs, it remains difficult to standardize their gating strategy by flow 
cytometry because of their lack of fully specific phenotypic markers. 
In human peripheral blood mononuclear cells (PBMC), monocytic (M)-MDSCs are defined 
as CD14pos HLA-DRlow CD15neg and PMN-MDSCs as CD11bpos CD14neg CD15pos (or 
CD66bpos) low-density granulocytes.1. Recently, a third subset so-called early-stage subset of 
MDSCs (e-MDSC) comprising more immature progenitors has been identified as Linneg 
(CD3/CD14/CD15/CD19/CD56) HLA-DRneg CD33pos CD11bpos cells lacking myeloid lineage 
markers of M-MDSCs and PMN-MDSCs.1,5 The existence of e-MDSC has been 
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demonstrated in renal cell carcinoma, epithelial ovarian cancer, and head and neck cancer but 
their suppressive function remains unproven.4,6,7 
Basophils represent 0.5-1% of peripheral leukocytes in normal conditions. They can be 
isolated within the PBMC fraction after a density gradient centrifugation, and are CD33pos 
CD11bpos HLA-DRneg CD3neg CD14neg CD19neg CD56neg, and for the most part CD15neg (i.e. 
Linneg).8 Thus, their phenotype overlaps with e-MDSCs, thereby leading to potential 
overestimation of respective cell type counts.  
 
To address this issue, we first analyzed peripheral blood from healthy donors (HDs, n=8) by 
flow cytometry using CD203c and CRTH2 antibodies ordered from Miltenyi Biotec (Bergich 
Gladbach, Germany), Lin-1 (CD3, CD14, CD16, CD19, CD20, CD56) from Becton 
Dickinson (BD Biosciences, San Jose, CA), and HLA-DR, CD33, and CD11b from Beckman 
Coulter (Brea, CA). We found that an average of 92.6% (range 78.5 to 98.2%) of Lin-1neg 
HLA-DRneg CD33pos CD11bpos cells expressed CD123 (interleukin 3 receptor α-chain) and 
CRTH2 (CD294, receptor for prostaglandin D2), consistently with a basophil phenotype 
(Figure 1A).9 Additionally, the expression of CD203c (ecto-nucleotide pyrophosphatase 
phosphodiesterase, specifically expressed by basophils and mast cells upon activation) was 
induced on CRTH2pos CD123pos cells from HDs (n=3) after 15 min of stimulation by an anti-
IgE antibody (Allergenicity kit, Beckman Coulter) (Figure 1B). Moreover, these cells released 
histamine after activation by anti-IgE, as measured by ELISA (data not shown). To confirm 
these findings, we sorted Lin-1neg HLA-DRneg CD33pos CD11bpos cells from a HD sample 
(FacsAriaIII, BD). Microscopic examination of cytospin slides stained with May-Grünwald-
Giemsa and captured at 1000x magnification revealed a mixture of basophils (characterized 
by their large purple-black granules and double-lobed nucleus) and immature myeloid cells 
with agranular cytoplasm containing vacuoles (presumably e-MDSCs) (Figure 1C). Finally, 
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and in accordance with a previous paper,8 we confirmed on 8 samples (n=6 HD and n=2 
diffuse large B-cell lymphoma, DLBCL) that on average only 9.4% (range 4.8 to 14%) of 
basophils expressed CD15 (Figure 1D). Consequently, the Linneg HLA-DRneg CD33pos 
phenotype encompasses a vast majority of basophils, which are not excluded by the CD15 
marker. 
Since circulating e-MDSC are increased in various types of cancers,4,6,7 we further analyzed 
20 DLBCL samples at diagnosis from a cohort already published by our group.3 The research 
protocol was conducted under French legal guidelines and fulfilled the requirements of the 
local institutional ethics committee; all patients provided written informed consent (BMS-
LyTRANS study; clinicaltrials.gov: NCT01287923). Clinical characteristics of DLBCL 
patients enrolled in this cohort are listed in Table 1. Within the Lin-1neg HLA-DRneg CD33pos 
CD11bpos population, we defined basophils and e-MDSCs as CD123pos and CD123neg 
fractions, respectively (Figure 1E). Basophils represented 68.3 % (range 4.1 to 97.6 %) of 
Lin-1neg HLA-DRneg CD33posCD11bpos cells (Figure 1E).  
 
Altogether, our results show that the Linneg HLA-DRneg CD33pos CD11bpos phenotype includes 
a heterogeneous population of functionally active mature basophils and immature myeloid 
cells morphologically consistent with e-MDSCs. The presence of basophils, often in large 
proportions, might account for the absence of clear suppressive phenotype in previous 
functional assays targeting e-MDSCs.4,6,7 Therefore, in addition to the recent 
recommendations,1 we suggest to include basophil-specific exclusion markers such as 
CRTH2/CD294 or CD123 in the reference panel, in order to refine the quantification of e-
MDSCs and to better define the clinical relevance of these cells. 
 
Fabrice Uhel, MD, PhDa,b 
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Table 1 Patients characteristics of the lymphoma cohort 
Characteristics Patients (n=20) 
Average age [range] (years) 54 [32-72] 
Male (n) 12 
Female (n) 8 
IPI (n) 
0-1 6 
2 3 
3 7 
4-5 4 
Cell of origin (n) 
GCB 5  
Non-GCB 9 
Unknown 6 
IPI: International Prognostic Index; GCB: Germinal 
Center B-cells 
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Figure legend 
 
Figure 1: Linneg HLA-DRneg CD33pos CD11bpos cells contain functional basophils 
A- On peripheral blood from healthy donors (HD), a subset of Linneg HLA-DRneg CD33pos 
CD11bpos cells express basophil markers CD123 and CRTH2. B- Expression of CD203c on 
Linneg HLA-DRneg CD33pos CD11bpos cells after anti-IgE stimulation. C- Linneg HLA-DRneg 
CD33pos CD11bpos cells observed on cytospin. Basophils (▲ ) and mononuclear cell 
suggestive of e-MDSC (◼ ). Scale bar represents 10 µm. D- Expression of CD15 on 
basophils (green) and neutrophils (blue). E- Linneg HLA-DRneg CD33pos CD11bpos cells were 
marked as CD123neg e-MDSCs (red) or CD123pos basophils (green) (top panels). Significant 
plots from one patient are shown. Data were acquired on a Navios flow cytometer (Beckman 
Coulter) and analyzed with Kaluza software (Beckman Coulter). 
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